Press Release Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial Results expected in May 2025 Last ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

The majority of our patients with ocular hypertension maintained IOP between 10 and 21 mm Hg across all treatment groups over time. Bai et al [4] also reported successful IOP control in their ...

Open-angle glaucoma and ocular hypertension require chronic topical treatment whose active ingredients can have some local side effects. Furthermore, different preservatives are present in the ...

Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ...

Emerging technologies, including remote tonometry and genetic risk scoring, hold promise for more efficient glaucoma care, ...

Generic Cosopt is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular ...

Excimer laser trabeculostomy reduced both IOP and medication burden in patients with open-angle glaucoma or ocular ...

NCX 470 0.1% achieved an intraocular pressure of less than or equal to 18 mmHg compared to latanoprost 0.005% in the trial.